ERBB2 and renal cell carcinoma: Importantly, a high rate of severe toxicities was observed for CAR-T therapies targeting TAAs including carbonic anhydrase IX (CA IX) in renal cell carcinoma (RCC) [154] and ERBB2 in metastatic CRC [155].